TLX

0.15%

$20.48 telix pharmaceuticals limited

every time i see a demonstration of Chatgpt I am amazed. Can it...

First 71 Last

Share
Profile

Follow
nottawombat

6,257 Posts.

582

26/07/24

19:17

Post #: 74938391
Share
Originally posted by Drian: ↑

someone may have done this before, if so, apologies (from chatGPT)

why have these companies issued convertible bond notes not regular shares i.e what are the advantages and these notes
ChatGPT
Biotech companies often opt for issuing convertible bond notes rather than regular shares for several strategic and financial reasons. Here’s a breakdown of why convertible bonds might be preferred:
**1. Lower Immediate Dilution
Convertible Bonds: These bonds can convert into equity (shares) at a future date, allowing the company to raise capital without immediately diluting existing shareholders' equity.
Regular Shares: Issuing new shares immediately dilutes existing shareholders' ownership, which can impact stock prices and existing equity value.
**2. Attractive Terms for Investors
Convertible Bonds: Offer a lower interest rate compared to traditional bonds because they provide the potential upside of converting into equity. This makes them attractive to investors who are willing to accept lower interest payments for the possibility of equity upside.
Regular Shares: Investors might demand higher returns or different terms if the company opts for a straightforward equity raise.
**3. Flexibility in Capital Raising
Convertible Bonds: Can be structured with various features such as conversion prices, maturity dates, and interest rates, providing flexibility in meeting financing needs and aligning with the company’s strategic goals.
Regular Shares: Are less flexible and involve immediate equity dilution, which might not be favorable if the company is in a period of rapid growth or undergoing significant changes.
**4. Potentially Lower Cost of Capital
Convertible Bonds: Typically have lower interest rates than non-convertible bonds due to the embedded option to convert into stock. This can be advantageous for biotech companies with limited cash flow.
Regular Shares: Raising equity might come with higher costs or affect the company's stock price negatively due to market reactions.
**5. Strategic Financing Tool
Convertible Bonds: Can be used to bridge financing needs while providing the company time to reach milestones that could potentially increase its stock price. If the company's stock price rises, conversion of the bonds can lead to additional capital without affecting the company's immediate financial standing.
Regular Shares: Might be more appropriate for companies in stable or mature stages, where immediate capital needs are pressing and the market conditions are favorable.
**6. Enhanced Investor Appeal
Convertible Bonds: Attract investors who are interested in the potential for equity upside and the fixed-income security of the bond. This can widen the pool of potential investors and potentially secure better financing terms.
Regular Shares: Might not attract as broad a range of investors, especially in the case of early-stage biotech firms where risk is high.
**7. Market Conditions
Convertible Bonds: Might be more favorable in volatile or uncertain market conditions where traditional equity offerings could be less attractive to investors or more challenging to execute.
Regular Shares: Can be less attractive in volatile markets where investors may be wary of equity dilution or unfavorable market reactions.
**8. Balance Sheet Management
Convertible Bonds: Initially appear as debt on the balance sheet, which can be advantageous for maintaining flexibility. As they convert to equity, the debt is reduced, potentially improving the company's debt-to-equity ratio over time.
Regular Shares: Increase equity immediately but do not provide the same flexibility or potential for debt reduction.
In summary, convertible bonds offer a hybrid financing option that provides flexibility, lower immediate dilution, and potentially lower costs compared to issuing regular shares, which can be particularly valuable for biotech companies with high growth potential and significant capital needs.

Expand

every time i see a demonstration of Chatgpt I am amazed.

Can it read womens minds ?

That would be a nice trick
TLX Price at posting: $19.32 Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 11 more messages in this thread...

First 71 Last

Add TLX (ASX) to my watchlist

(20min delay)
Last $20.48		Change 0.030(0.15%)		Mkt cap ! $6.854B

Open	High	Low	Value	Volume
$20.35	$20.83	$20.30	$10.68M	520.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1586	$20.48

Sellers (Offers)

Price($)	Vol.	No.
$20.58	898	2

View Market Depth

No.	Vol.	Price($)
1	387	20.410
1	196	20.400
1	2	20.300
1	1000	20.290
1	300	20.160

Price($)	Vol.	No.
20.700	4500	1
20.750	500	1
20.800	1792	2
20.880	1784	2
20.890	3000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

TLX (ASX) Chart

every time i see a demonstration of Chatgpt I am amazed. Can it...

1. Lower Immediate Dilution**

2. Attractive Terms for Investors**

3. Flexibility in Capital Raising**

4. Potentially Lower Cost of Capital**

5. Strategic Financing Tool**

6. Enhanced Investor Appeal**

7. Market Conditions**

8. Balance Sheet Management**

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

every time i see a demonstration of Chatgpt I am amazed. Can it...

**1. Lower Immediate Dilution

**2. Attractive Terms for Investors

**3. Flexibility in Capital Raising

**4. Potentially Lower Cost of Capital

**5. Strategic Financing Tool

**6. Enhanced Investor Appeal

**7. Market Conditions

**8. Balance Sheet Management

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

1. Lower Immediate Dilution**

2. Attractive Terms for Investors**

3. Flexibility in Capital Raising**

4. Potentially Lower Cost of Capital**

5. Strategic Financing Tool**

6. Enhanced Investor Appeal**

7. Market Conditions**

8. Balance Sheet Management**